In April 2016 Manchester eScholar was replaced by the University of Manchester’s new Research Information Management System, Pure. In the autumn the University’s research outputs will be available to search and browse via a new Research Portal. Until then the University’s full publication record can be accessed via a temporary portal and the old eScholar content is available to search and browse via this archive.

Related resources

Full-text held externally

University researcher(s)

    Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

    Cole, Claire; Lau, Sin; Backen, Alison; Clamp, Andrew; Rushton, Graham; Dive, Caroline; Hodgkinson, Cassandra; McVey, Rhona; Kitchener, Henry; Jayson, Gordon C

    Cancer biology & therapy. 2010;10(5).

    Access to files

    Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:

    Full-text held externally

    Abstract

    Fibroblast Growth Factors (FGFs) have been implicated in malignant transformation, tumor mitogenesis, angiogenesis and chemoresistance. The aim of this study was to determine which FGFs and FGFRs play functional roles in epithelial ovarian cancer. Restriction enzyme analysis of mRNA revealed that transformation was associated with a switch in FGFR2 and FGFR3, from the IIIc to the IIIb isoform. There was widespread expression of FGFs, including FGF7, in all tissues but, FGF3 and FGF19 were expressed by malignant cell lines and cancer tissue but were not present in normal tissue. Using FGFR-specific shRNAi we demonstrated that reductions in FGFR2 inhibited proliferation of ovarian cancer cell lines in vitro (>50%, p < 0.006) and reduced cisplatin IC(50) (>60%, p < 0.0001). Cell cycle analysis revealed increased cisplatin sensitivity was associated with increased G(2)/M arrest and increased apoptosis. FGFR2 shRNAi reduced growth rates of ovarian tumor xenografts by 20% (p > 0.006) and when combined with cisplatin caused a 40% reduction in proliferation rates (p < 0.007). In contrast, RNAi-induced reductions in FGFR1 increased SKOV3 cell numbers, with associated changes in cell cycle but had no effect on ES2 cells. However, the cisplatin IC(50) was reduced (>50%, p < 0.0001) by FGFR1 shRNAi in both cell lines and there was increased apoptosis (46-50%) compared with control cells (35%) (p > 0.004). Together our data suggest that combining FGFR2 inhibitors with platinum-containing cytotoxic agents for the treatment of epithelial ovarian cancer may yield increased anti-tumor activity. However, data on the inhibition of FGFR1 suggest that broad spectrum FGFR inhibitors may have unexpected effects on proliferation.

    Bibliographic metadata

    Type of resource:
    Content type:
    Published date:
    Journal title:
    Abbreviated journal title:
    ISSN:
    Volume:
    10
    Issue:
    5
    Digital Object Identifier:
    10.4161/cbt.10.5.12585
    Pubmed Identifier:
    20595807
    Pii Identifier:
    12585
    Access state:
    Active

    Institutional metadata

    University researcher(s):

    Record metadata

    Manchester eScholar ID:
    uk-ac-man-scw:88539
    Created by:
    Kitchener, Henry
    Created:
    25th August, 2010, 10:06:50
    Last modified by:
    Kitchener, Henry
    Last modified:
    11th April, 2016, 09:04:31

    Can we help?

    The library chat service will be available from 11am-3pm Monday to Friday (excluding Bank Holidays). You can also email your enquiry to us.